References

1. Ahsan H, Neugut AI, Garbowski GC. et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med. 1998;128(11):900–905. Exclusion: Not about accuracy and tool not standardized. [PubMed: 9634428]
2. Alberto VO, Harocopos CJ, Patel AA. et al. Family and personal history in colorectal cancer patients: what are we missing? Int J Colorectal Dis. 2006;8(7):612–614. Exclusion: Does not apply to any of the research questions. [PubMed: 16919116]
3. Altieri A, Hemminki K. Number of siblings and the risk of solid tumours: a nation-wide study. Br J Cancer. 2007 6–4;96(11):1755–1759. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC2359906] [PubMed: 17453006]
4. American Gastroenterological Association. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121(1):195–197. Exclusion: Study Type. [PubMed: 11438508]
5. Amir E, Evans DG, Shenton A. et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003;40(11):807–814. Exclusion: Guideline or consensus statement. [PMC free article: PMC1735317] [PubMed: 14627668]
6. Andermann A, Narod SA. Genetic counselling for familial breast and ovarian cancer in Ontario. J Med Genet. 2002;39( 9):695–696. Exclusion: No data reported. [PMC free article: PMC1735233] [PubMed: 12205116]
7. Anderson WF, Matsuno RK, Sherman ME. et al. Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes Control. 2007;18(4):439–447. Exclusion: Not about accuracy and tool not standardized. [PubMed: 17216325]
8. Anonymous. American Gastroenterology Association issues guidelines for colorectal cancer screening. Am Fam Physician 1997;55(8):2860–2862,286. Exclusion: Study Type. [PubMed: 9206931]
9. Anonymous. Assessing hereditary breast cancer risk. Cancer Pract 1999;7(6):279–284. Exclusion: Not about accuracy and tool not standardized. [PubMed: 10732524]
10. Anonymous. Colorectal cancer screening. Recommendation statement from the Canadian Task Force on Preventive Health Care. Can Fam Physician 2001;47(Sept):1811–1815. Exclusion: Study Type. [PMC free article: PMC2018577] [PubMed: 11570307]
11. Anonymous. Colorectal cancer screening: New recommendations. Consultant 2003;43(3):318–320. Exclusion: No data reported.
12. Anonymous. Raising concerns about family history of breast cancer in primary care consultations: prospective, population based study. BMJ 2001;322(7277):27–28. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC26605] [PubMed: 11141150]
13. Antill YC, Shanahan M, Phillips KA. The integrated, multidisciplinary clinic: A new model for the ongoing management of women at high genetic risk for breast and ovarian cancer. Cancer Forum. 2005;29(2):107–110. Exclusion: Not about accuracy and tool not standardized.
14. Antoniou AC, Durocher F, Smith P et al. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Research. 2006;8(1):R. Exclusion: Only a mutation or prediction. [PMC free article: PMC1413985] [PubMed: 16417652]
15. Bajdik CD, Raboud JM, Schechter MT. et al. A computer model to simulate family history of breast/ovarian cancer in BRCA1 mutation carriers. Math Biosci. 2001;171(1):99–111. Exclusion: Only a mutation or prediction. [PubMed: 11325386]
16. Balmana J, Stockwell DH, Steyerberg EW. et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA. 2006;296(12):1469–1478. Exclusion: Guideline or consensus statement. [PubMed: 17003395]
17. Bankhead C, Emery J, Qureshi N. et al. New developments in genetics: Knowledge, attitudes and information needs of practice nurses. Fam Pract. 2001;18(5):475–486. Exclusion: Presents only aggregate data. [PubMed: 11604367]
18. Barcenas CH, Hosain GM, Arun B. et al. Assessing BRCA carrier probabilities in extended families. Jpn J Clin Oncol. 2006;24(3):354–360. Exclusion: Only a mutation or prediction. [PubMed: 16421416]
19. Bartlett S. Predictive model for hereditary colorectal cancer. Lancet Oncol. 2006;7(8):62. Exclusion: Narrative only. [PubMed: 16900599]
20. Becher H, Chang-Claude J. Estimating disease risks for individuals with a given family history in different populations with an application to breast cancer. Genet Epidemiol. 1996;13(3):229–242. Exclusion: Only a mutation or prediction. [PubMed: 8797006]
21. Beckmann MW, Schnurch HG, Bodden-Heidrich R. et al. Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines. Eur J Cancer Prev. 1996;5(6):468–475. Exclusion: Study type. [PubMed: 9061278]
22. Beebe-Dimmer JL, Drake EA, Dunn RL. et al. Association between family history of prostate and breast cancer among African-American men with prostate cancer. Urology. 2006;68(5):1072–1076. Exclusion: Does not apply to any of the research questions. [PubMed: 17095075]
23. Bell R, Petticrew M. Screening people with a family history of cancer. Benefit of screening for ovarian cancer is unproved. BMJ. 1997 11–15;315(7118):130. Exclusion: No data reported. [PMC free article: PMC2127786] [PubMed: 9390065]
24. Benichou J. A computer program for estimating individualized probabilities of breast cancer.[erratum appears in Comput Biomed Res 1994 Feb;27(1):81] Computers & Biomedical Research. 1993;26(4):373–382. Exclusion: Narrative only. [PubMed: 8403860]
25. Bennett C, Burton H, Farndon P. Competences, education and support for new roles in cancer genetics services: Outcomes from the cancer genetics pilot projects. Fam Cancer. 2007;6(2):171–180. Exclusion: Not about accuracy and tool not standardized. [PubMed: 17520353]
26. Bergmann M, Wolf B, Karner-Hanusch J. Hereditary colorectal cancer - Guidelines for clinical routine. European Surgery - Acta Chirurgica Austriaca Supplement. 2006;38(1):59–62. Exclusion: Study Type.
27. Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: Recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007;16(3):241–260. Exclusion: Not about accuracy and tool not standardized. [PubMed: 17508274]
28. Bhatia S, Pratt CB, Sharp GB. et al. Family history of cancer in children and young adults with colorectal cancer. Med Pediatr Oncol. 1999;33(5):470–475. Exclusion: Population. [PubMed: 10531571]
29. Biswas S, Berry DA. Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods. Genet Epidemiol. 2005;29(2):141–154. Exclusion: Study Type. [PubMed: 16025444]
30. Blazer KR, Grant M, Sand SR. et al. Effects of a cancer genetics education programme on clinician knowledge and practice. J Med Genet. 2004;41(7):518–522. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC1735845] [PubMed: 15235022]
31. Blazer KR, MacDonald DJ, Ricker C. et al. Outcomes from intensive training in genetic cancer risk counseling for clinicians. Genetics in Medicine. 2005;7(1):40–47. Exclusion: No cancer of interest. [PubMed: 15654227]
32. Bodmer D, Ligtenberg MJL, Van Der. et al. Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ‘easy to apply’ probability models. Br J Cancer. 2006;95(6):757–762. Exclusion: Guideline or consensus statement. [PMC free article: PMC2360521] [PubMed: 16909138]
33. Bonadona V, Sinilnikova OM, Chopin S. et al. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes Chromosomes Cancer. 2005;43(4):404–413. Exclusion: Not about accuracy and tool not standardized. [PubMed: 15887246]
34. Bonadona V, Sinilnikova OM, Lenoir GM. et al. Re: Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO (multiple letters) [2] J Natl Cancer Inst. 2002;94(20):1582–1584. Exclusion: Only a mutation or prediction. [PubMed: 12381714]
35. Braithwaite D, Sutton S, Smithson WH. et al. Internet-based risk assessment and decision support for the management of familial cancer in primary care: a survey of GPs' attitudes and intentions. Fam Pract. 2002;19(6):587–59. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12429659]
36. Brennan P, Claber O, Shaw T. The Teesside Cancer Family History Service: Change management and innovation at cancer network level. Fam Cancer. 2007;6(2):181–187. Exclusion: Does not apply to any of the research questions. [PubMed: 17508271]
37. Burke W, Daly M, Garber J. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. JAMA. 1997;277(12):997–100. Exclusion: Study Type. [PubMed: 9091675]
38. Burke W, Petersen G, Lynch P. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I. Hereditary nonpolyposis colon cancer. JAMA. 1997;277(11):915–91. Exclusion: Study Type. [PubMed: 9062331]
39. Burrer CV, Bauer SM. Insights into genetic testing for colon cancer: the nurse practitioner role. Clin Excell Nurse Pract. 2000;4( 6):349–355. Exclusion: Study type. [PubMed: 11858318]
40. Calzone KA, Stopfer J, Blackwood A. et al. Establishing a cancer risk evaluation program. Cancer Practice: A Multidisciplinary Journal of Cancer Care. 1997;5(4):228–233. Exclusion: No data reported. [PubMed: 9250079]
41. Camp NJ, Slattery ML. Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States). Cancer Causes Control. 2002;13(9):813–823. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12462546]
42. Capalbo C, Ricevuto E, Vestri A. et al. Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. Eur J Hum Genet. 2006;14(1):49–54. Exclusion: Only a mutation or prediction. [PubMed: 16288312]
43. Carayol J, Khlat M, Maccario J. et al. Hereditary non-polyposis colorectal cancer: current risks of colorectal cancer largely overestimated. J Med Genet. 2002;39(5):335–339. Exclusion: Only a mutation or prediction. [PMC free article: PMC1735123] [PubMed: 12011152]
44. Casadei S, Falcini F, Naldoni C. et al. Population-based screening for hereditary breast cancer in a region of North-Central Italy. Int J Mol Med. 2002;10(3):299–305. Exclusion: Guideline or consensus statement. [PubMed: 12165804]
45. Catherino WH, Andolsek K. Women at high risk for breast cancer: A primary care perspective. --- 1998;5(6):268–275. Exclusion: Study type.
46. Chang-Claude J, Becher H, Caligo M. et al. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. Dis Markers. 1999;15(13):53–65. Exclusion: Only a mutation or prediction. [PMC free article: PMC3850798] [PubMed: 10595253]
47. Chatterjee N, Kalaylioglu Z, Shih JH. et al. Case-control and case-only designs with genotype and family history data: estimating relative risk, residual familial aggregation, and cumulative risk. Biometrics. 2006;62(1):36–48. Exclusion: Only a mutation or prediction. [PubMed: 16542227]
48. Chatterjee N, Shih J, Hartge P. et al. Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study. Genet Epidemiol. 2001;21(2):123–138. Exclusion: Only a mutation or prediction. [PubMed: 11507721]
49. Chen S, Wang W, Lee S. et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006;296(12):1479–1487. Exclusion: Only a mutation or prediction. [PMC free article: PMC2538673] [PubMed: 17003396]
50. Church JM. A scoring system for the strength of a family history of colorectal cancer. Dis Colon Rectum. 2005;48(5):889–896. Exclusion: Does not apply to any of the research questions. [PubMed: 15785893]
51. Church J, Lowry A, Simmang C. et al. Practice parameters for the identification and testing of patients at risk for dominantly inherited colorectal cancer—supporting documentation. Dis Colon Rectum. 2001;44(10):1404–1412. Exclusion: Only a mutation or prediction. [PubMed: 11598466]
52. Church J, McGannon E. Family history of colorectal cancer: how often and how accurately is it recorded? Dis Colon Rectum. 2000;43(11):1540–1544. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11089589]
53. Clark SK, Carpenter S, Broughton CIM. et al. Surveillance of individuals at intermediate risk of colorectal cancer - The impact of new guidelines. Int J Colorectal Dis. 2003;5(6):582–584. Exclusion: Not about accuracy and tool not standardized. [PubMed: 14617245]
54. Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat. 2003;78(1):7–15. Exclusion: Guideline or consensus statement. [PubMed: 12611452]
55. Clough GR. Taking control of family history screening. Synergy 2003;15–7. Exclusion: No data reported.
56. Cochrane RA, Davies EL, Singhal H. et al. The National Breast Referral Guidelines have cut down inappropriate referrals in the under 50s. Eur J Surg Oncol. 1999;25(3):251–254. Exclusion: Not about accuracy and tool not standardized. [PubMed: 10336802]
57. Cohen MM. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet. 1994;55(5):i–iv. Exclusion: Study type. [PMC free article: PMC1918344] [PubMed: 7977337]
58. Colombet I, Xu Y, Jaulent MC et al. A generic computerized method for estimate of familial risks. Proceedings / AMIA ...Annual Symposium.2002:175-. Exclusion: Presents only aggregate data. [PMC free article: PMC2244401] [PubMed: 12463810]
59. Cortesi L, Turchetti D, Marchi I. et al. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. BMC Cancer. 2006;6:21. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC1578585] [PubMed: 16916448]
60. Cortizo-Torres ME, Duarte F, Schmitt FC. et al. Criteria for definition of hereditary breast cancer in a clinic perspective. Breast J. 2002;8(6):402–403. Exclusion: Only a mutation or prediction. [PubMed: 12390370]
61. Coulson AS, Glasspool DW, Fox J. et al. RAGs: A novel approach to computerized genetic risk assessment and decision support from pedigrees. Methods Inf Med. 2001;40(4):315–322. Exclusion: Narrative only. [PubMed: 11552344]
62. Couto E, Hemminki K. Estimates of heritable and environmental components of familial breast cancer using family history information. Br J Cancer. 2007;96(11):1740–1742. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC2359918] [PubMed: 17473828]
63. Cuzick J. Epidemiology of breast cancer—selected highlights. Breast. 2003;12(6):405–411. Exclusion: Study Type. [PubMed: 14659113]
64. Daly MB, Axilbund JE, Bryant E. et al. Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2006;4(2):156–176. Exclusion: Study Type. [PubMed: 16451772]
65. Daly M, Farmer J, Harrop-Stein C. et al. Exploring family relationships in cancer risk counseling using the genogram. Cancer Epidemiol Biomarkers Prev. 1999;8(4 Pt 2):393–398. Exclusion: Not about accuracy and tool not standardized. [PubMed: 10207645]
66. Daly PA. Hereditary cancer: Guidelines in clinical practice - General overview. Ann Oncol. 2004;15(SUPPL. 4):iv121–iv125. Exclusion: Study Type. [PubMed: 15477294]
67. de Bock GH, van Asperen CJ, de Vries JM. et al. How women with a family history of breast cancer and their general practitioners act on genetic advice in general practice: Prospective longitudinal study. Br Med J. 2001;322(7277):26–27. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC26604] [PubMed: 11141149]
68. de Bock GH, Vliet Vlieland TPM, Hageman GCHA. et al. The assessment of genetic risk of breast cancer: A set of GP guidelines. Fam Pract. 1999;16(1):71–77. Exclusion: Does not apply to any of the research questions. [PubMed: 10321400]
69. de Bock GH, Vliet Vlieland TPM, Hakkeling M. et al. GPs' management of women seeking help for familial breast cancer. Fam Pract. 1999;16(5):463–467. Exclusion: Not about accuracy and tool not standardized. [PubMed: 10533941]
70. de Bock GH, van Asperen CJ, de Vries JM. et al. How women with a family history of breast cancer and their general practitioners act on genetic advice in general practice: prospective longitudinal study. BMJ. 2001;322(7277):26–27. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC26604] [PubMed: 11141149]
71. de Bock GH, Vlieland TP, Hakkeling M. et al. GPs' management of women seeking help for familial breast cancer. Fam Pract. 1999;16(5):463–467. Exclusion: Not about accuracy and tool not standardized. [PubMed: 10533941]
72. de la Hoya M, Perez-Segura P, Van Orsouw N. et al. Spanish family study on hereditary breast and/or ovarian cancer: analysis of the BRCA1 gene. Int J Cancer. 2001;91(1):137–140. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11149413]
73. DeMarco TA, Loffredo CA, Sampilo ML. et al. On using a cancer center cancer registry to identify newly affected women eligible for hereditary breast cancer syndrome testing: practical considerations. J Genet Couns. 2006;15(2):129–136. Exclusion: Not about accuracy and tool not standardized. [PubMed: 16761104]
74. Dominguez FJ, Jones JL, Zabicki K. et al. Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer. 2005;104(9):1849–1853. Exclusion: Guideline or consensus statement. [PubMed: 16136597]
75. Donohue-Moore M. Commentary on Patterns of inheritance of ovarian cancer: an analysis from an ovarian cancer screening program. ONS Nursing Scan in Oncology. 1994;3(2):2. Exclusion: Presents only aggregate data.
76. Douglas FS, O'Dair LC, Robinson M. et al. The accuracy of diagnoses as reported in families with cancer: a retrospective study. J Med Genet. 1999;36(4):309–312. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC1734350] [PubMed: 10227399]
77. Eccles DM, Evans DGR, Mackay J. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. J Med Genet. 2000;37(3):203–209. Exclusion: Study Type. [PMC free article: PMC1734545] [PubMed: 10699057]
78. Eccles DM, Kennedy R, Quinn J. et al. Genetic testing for BRCA1 mutation in the UK [4] (multiple letters). Lancet. 2003;361( 9352):178–179. Exclusion: No data reported. [PubMed: 12531609]
79. Eisinger F, Horsman DE. Genetic risk assessment and BRCA mutation testing. Ann Intern Med. 2006;144( 5):376–377. Exclusion: Study Type. [PubMed: 16520482]
80. Eisinger F, Reynier CJ, Chabal F. et al. Acceptable strategies for dealing with hereditary breast/ovarian cancer risk. J Natl Cancer Inst. 1997;89(10):73. Exclusion: Not about accuracy and tool not standardized. [PubMed: 9168189]
81. Eisinger F, Sobol H. Comments on: Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics, Vasen et al., Eur J Cancer 1998, 34, 1922–1926. Eur J Cancer 1999;35(5):859–860. Exclusion: Narrative only. [PubMed: 10505049]
82. Emery J. Familial breast cancer. Fam Pract. 1997;14(5):42. Exclusion: No data reported. [PubMed: 9472379]
83. Escher M, Sappino AP. Primary care physicians' knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol. 2000;11(9):1131–1135. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11061607]
84. Euhus DM, Leitch AM, Huth JF. et al. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J. 2002;8( 1):23–27. Exclusion: Guideline or consensus statement. [PubMed: 11856157]
85. Euhus DM, Smith KC, Robinson L. et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002;94( 11):844–851. Exclusion: Only a mutation or prediction. [PubMed: 12048272]
86. Evans DG, Easton D. Family history of breast cancer: referral guidelines changed after acceptance of 10 minute consultation. BMJ. 2005;330( 7493):73. Exclusion: No data reported. [PMC free article: PMC555645] [PubMed: 15790649]
87. Evans DG, Eccles DM, Rahman N. et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004;41(6):474–480. Exclusion: Guideline or consensus statement. [PMC free article: PMC1735807] [PubMed: 15173236]
88. Evans DG, Lalloo F, Wallace A. et al. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet. 2005;42(7):e3. Exclusion: Only a mutation or prediction. [PMC free article: PMC1736089] [PubMed: 15994864]
89. Evans D, Lalloo F, Shenton A. et al. Uptake of screening and prevention in women at very high risk of breast cancer. Lancet. 2001;358( 9285):889–890. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11567707]
90. Evans G, Eeles R. Hereditary cancer. Lancet Oncol. 2000;1(1):12–13. Exclusion: No data reported. [PubMed: 11905676]
91. Evans S, Lynch HT, Fusaro RM. Clinical results using informatics to evaluate hereditary cancer risk. Proceedings - the Annual Symposium on Computer Applications in Medical Care 1995:834-. Exclusion: Presents only aggregate data. [PMC free article: PMC2579211] [PubMed: 8563409]
92. Farraye F, Gangarosa L, Burt RW. et al. American Gastroenterological Association Medical Position Statement: Hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121(1):195–197. Exclusion: Study Type. [PubMed: 11438508]
93. Federico M, Maiorana A, Mangone L. et al. Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: the Modena Study Group proposal. Breast Cancer Res Treat. 1999;55(3):213–221. Exclusion: Guideline or consensus statement. [PubMed: 10517166]
94. Fidalgo PO, Cravo ML, Nobre-Leitao C. Re: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda Guidelines. J Natl Cancer Inst. 1998;90(12):939–940. Exclusion: Study Type. [PubMed: 9637147]
95. Floderus B, Barlow L, Mack TM. Recall bias in subjective reports of familial cancer. Am J Epidemiol. 1990;1(4):318–321. Exclusion: Not about accuracy and tool not standardized. [PubMed: 2083311]
96. Fornasarig M, Viel A, Bidoli E. et al. Amsterdam criteria II and endometrial cancer index cases for an accurate selection of HNPCC families. Tumori. 2002;88( 1):18–20. Exclusion: No cancer of interest. [PubMed: 12004844]
97. Foulkes WD, Brunet JS, Warner E. et al. The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet. 1999;65(6):1776–1779. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC1288389] [PubMed: 10577933]
98. Foulkes W, Glendon G, Narod S. Family history and risk of ovarian cancer. JAMA. 1995;274(5):38. Exclusion: No data reported. [PubMed: 7616630]
99. Friedenson B. Assessing and managing breast cancer risk: Clinical tools for advising patients. Medgenmed [Computer File]: Medscape General Medicine 2004;6(1). Exclusion: Study type. [PMC free article: PMC1140711] [PubMed: 15208521]
100. Fries MH, Holt C, Carpenter I. et al. Guidelines for evaluation of patients at risk for inherited breast and ovarian cancer: recommendations of the Department of Defense Familial Breast/Ovarian Cancer Research Project. Mil Med. 2002;167(2):93–98. Exclusion: Study Type. [PubMed: 11873549]
101. Furukawa T, Konishi F, Shitoh K. et al. Evaluation of screening strategy for detecting hereditary nonpolyposis colorectal carcinoma. Cancer. 2002;94(4):911–920. Exclusion: Only a mutation or prediction. [PubMed: 11920458]
102. Garbers V, Toniolo PG, Taioli E. Changes in self-reported family history of breast cancer with change in case-control status. Eur J Epidemiol. 2001;17(6):517–520. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11949722]
103. Garcia-Patino E, Gomendio B, Silva JM. et al. BRCA1 mutations in patients with familial risk of breast cancer. Acta Oncol (Madr). 1998;37(3):299–300. Exclusion: Study Type. [PubMed: 9677103]
104. Glasspool DW, Fox J, Coulson AS. et al. Risk assessment in genetics: a semi-quantitative approach. Medinfo. 2001;10( Pt 1):459–463. Exclusion: Study Type. [PubMed: 11604782]
105. Goelen G, Teugels E, Sermijn E. et al. Comparing the performance of family characteristics and predictive models for germline BRCA1/2 mutations in breast cancer families. Archives of Public Health. 2003;61(6):297–312. Exclusion: Only a mutation or prediction.
106. Goetsch CM, Smith SM, Olopade OI. et al. Multidisciplinary rounds. Assessing hereditary breast cancer risk. Cancer Practice: A Multidisciplinary Journal of Cancer Care. 1999;7(6):279–284. Exclusion: Study Type. [PubMed: 10732524]
107. Gramling R, Anthony D, Simmons E. et al. Self-rated breast cancer risk among women reporting a first-degree family history of breast cancer on office screening questionnaires in routine medical care: the role of physician-delivered risk feedback. Genet Med. 2006;8(10):658–664. Exclusion: Does not apply to any of the research questions. [PubMed: 17079883]
108. Gray E, Rothnie N, Fowler A. Family histories of cancer in primary care. Nurse led clinic may provide better service than computer program. BMJ. 2000;321(7266):95. Exclusion: No data reported. [PubMed: 11030696]
109. Gray RE, Chart P, Carroll JC. et al. Family physicians' perspectives on ovarian cancer. Cancer Prevention & Control. 1999;3(1):61–67. Exclusion: Not about accuracy and tool not standardized. [PubMed: 10474754]
110. Grumet SC, Bruner DW. The identification and screening of men at high risk for developing prostate cancer. Urol Nurs 2000;20(1):15–8,23–4,46. Exclusion: No data reported. [PubMed: 11998038]
111. Gui GPH, Hogben RKF, Walsh G. et al. The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography? Eur J Cancer. 2001;37(13):1668–1673. Exclusion: Only a mutation or prediction. [PubMed: 11527694]
112. Guillem JG. Need for screening colonoscopy in first-degree relatives. Gastroenterology. 1997;112(6):2161–2162. Exclusion: No data reported. [PubMed: 9178719]
113. Gulzar Z, Goff S, Njindou A. et al. Nurse-led cancer genetics clinics in primary and secondary care in varied ethnic population areas: Interaction with primary care to improve ascertainment of individuals from ethnic minorities. Fam Cancer. 2007;6(2):205–212. Exclusion: Does not apply to any of the research questions. [PubMed: 17508270]
114. Gurmankin Levy A, Shea J, Williams SV. et al. Measuring perceptions of breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1893–1898. Exclusion: Does not apply to any of the research questions. [PubMed: 17035396]
115. Hakama M. Family history in colorectal cancer surveillance strategies. Lancet. 2006;368( 9530):101–103. Exclusion: No data reported. [PubMed: 16829281]
116. Hampel H, Sweet K, Westman JA. et al. Referral for cancer genetics consultation: A review and compilation of risk assessment criteria. J Med Genet. 2004;41(2):81–91. Exclusion: Presents only aggregate data. [PMC free article: PMC1735676] [PubMed: 14757853]
117. Hapgood R, Qureshi N, Allen J. Breast cancer genetics in primary care: Which GPs most accurately categorise patients at low risk? Eur J Gen Pract. 2002;8(4):146–150. Exclusion: Not about accuracy and tool not standardized.
118. Hartenbach EM, Becker JM, Grosen EA. et al. Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2. Genet Test. 2002;6(2):75–78. Exclusion: Only a mutation or prediction. [PubMed: 12229876]
119. Hemminki K, Chen B. Familial risk for colon and rectal cancers. Int J Cancer. 2004;111(5):809–810. Exclusion: Not about accuracy and tool not standardized. [PubMed: 15252856]
120. Hicken GJ, Francis A, Harries SA. Hereditary breast cancer. Br J Surg. 1998;85(4):570–571. Exclusion: No data reported. [PubMed: 9607548]
121. Hill A, McDermott E, O'Higgins N. Hereditary breast cancer. Br J Surg. 1998;85(8):115. Exclusion: No data reported. [PubMed: 9718021]
122. Hodgson SV, Bishop DT, Dunlop MG. et al. Suggested screening guidelines for familial colorectal cancer. J Med Screen. 1995;2(1):45–51. Exclusion: Study Type. [PubMed: 7497146]
123. Hodgson SV, Mohammed SN. Screening for breast cancer. Consider family history also. BMJ. 1994;309(6955):66. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC2541517] [PubMed: 8086995]
124. Hoskins KF, Zwaagstra A, Ranz M. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer. 2006;107(8):1769–1776. Exclusion: Does not apply to any of the research questions. [PubMed: 16967460]
125. Hoskins Kent F, Stopfer Jill E, Calzone Kathleen A. et al. Assessment and counseling for women with a family history of breast cancer: A guide for clinicians. JAMA. 1995;273(7):577–585. Exclusion: No data reported. [PubMed: 7837392]
126. Huelsman KM, Huppert J, Fiorica J. Screening your patients for inherited breast and ovarian cancer: how to collect family history data. Contemp Ob Gyn 1998;43(11):107–8,111–2,114. Exclusion: Study type.
127. Hughes KS, Roche CA, Whitney T. et al. The management of women at high risk of experiencing hereditary breast and ovarian cancer: The lahey guidelines. Disease Management & Health Outcomes. 2000;7(4):201–215. Exclusion: Study type.
128. Hunt L, Armitage NC. Screening for large bowel neoplasms in individuals with a family history of colorectal neoplasms. Br J Surg. 1992;79(12):1384–1385. Exclusion: No data reported. [PubMed: 1486450]
129. Husson G, Herrinton LJ. How accurately does the medical record capture maternal history of cancer? Cancer Epidemiol Biomarkers Prev. 2000;9(7):765–768. Exclusion: Not about accuracy and tool not standardized. [PubMed: 10919750]
130. Iredale R, Brain K, Gray J. et al. The information and support needs of women at high risk of familial breast and ovarian cancer: how can cancer genetic services give patients what they want? Fam Cancer. 2003;2(2):119–121. Exclusion: Not about accuracy and tool not standardized. [PubMed: 14649669]
131. Irmejs A, Borosenko V, Melbarde-Gorkusa I. et al. Nationwide study of clinical and molecular features of hereditary non-polyposis colorectal cancer (HNPCC) in Latvia. Anticancer Res. 2007;27(1B):653–658. Exclusion: Not about accuracy and tool not standardized. [PubMed: 17348456]
132. Irwin DE, Millikan RC, Stevens R. et al. Genomics and public health practice: a survey of nurses in local health departments in North Carolina. J Public Health Manag Pract. 2004;10(6):539–544. Exclusion: No cancer of interest. [PubMed: 15643378]
133. Jacobi CE, Jonker MA, Nagelkerke NJ. et al. Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care. J Med Genet. 2003;40(7):e8. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC1735526] [PubMed: 12843332]
134. Jacobi CE, van Ierland Y, van Asperen CJ. et al. Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort. Genet Med. 2007;9(3):173–179. Exclusion: Not about accuracy and tool not standardized. [PubMed: 17413421]
135. Jacobs C, Rawson R, Campion C. et al. Providing a community-based cancer risk assessment service for a socially and ethnically diverse population. Fam Cancer. 2007;6(2):189–195. Exclusion: Does not apply to any of the research questions. [PubMed: 17520349]
136. Jacobs LA. Author reexamines literature on genetics and hereditary nonpolyposis colon cancer. Oncol Nurs Forum. 1998;25(6):97. Exclusion: Narrative only. [PubMed: 9679249]
137. James PA, Doherty R, Harris M. et al. Optimal selection of individuals for BRCA mutation testing: A comparison of available methods. J Clin Oncol. 2006;24(4):707–715. Exclusion: Not about accuracy and tool not standardized. [PubMed: 16446345]
138. James PA, Parry S, Arnold J. et al. Confirming a diagnosis of hereditary colorectal cancer: The impact of a familial bowel cancer registry in New Zealand. N Z Med J. 2006;119(1242):1–6. Exclusion: Does not apply to any of the research questions. [PubMed: 16998569]
139. Jass JR. Screening for familial colorectal cancer. Gut. 1996;39(3):49. Exclusion: No data reported. [PMC free article: PMC1383371] [PubMed: 8949666]
140. John EM, Hopper JL, Beck JC. et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004;6(4):R375–R389. Exclusion: Study Type. [PMC free article: PMC468645] [PubMed: 15217505]
141. Johnson J, Giles RT, Larsen L. et al. Utah's Family High Risk Program: bridging the gap between genomics and public health. Prev Chronic Dis. 2005;2(2):A2. Exclusion: Presents only aggregate data. [PMC free article: PMC1327718] [PubMed: 15888235]
142. Jonker MA, Jacobi CE, Hoogendoorn WE. et al. Modeling familial clustered breast cancer using published data. Cancer Epidemiol Biomarkers Prev. 2003;12( 2):1479–1485. Exclusion: Not about accuracy and tool not standardized. [PubMed: 14693741]
143. Julian-Reynier C, Eisinger F, Moatti JP. et al. Re: Randomized trial of a specialist genetic assessment service for familial breast cancer. J Natl Cancer Inst. 2001;93(2):158–159. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11208894]
144. Kalra P, Togami J, Bansal BSG. et al. A neurocomputational model for prostate carcinoma detection. Cancer. 2003;98(9):1849–1854. Exclusion: Not about accuracy and tool not standardized. [PubMed: 14584066]
145. Kaufman DJ, Struewing JP. Re: Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst. 1999;91(14):1250–1251. Exclusion: No data reported. [PubMed: 10413427]
146. Kazerouni N, Greene MH, Lacey JVJ. et al. Family history of breast cancer as a risk factor for ovarian cancer in a prospective study. Cancer. 2006;107(5):1075–1083. Exclusion: Not about accuracy and tool not standardized. [PubMed: 16881078]
147. Kefford R, Tucker K, Friedlander M. et al. Cancer in the family: part 2. Aust Fam Physician. 1998;27(1/2):40–44. Exclusion: No data reported. [PubMed: 9503704]
148. Keinan-Boker L, Baron-Epel O, Garty N. et al. Family history of breast cancer and compliance with mammography in Israel: findings of the National Health Survey 2003-2004 (EUROHIS). Eur J Cancer Prev. 2007;16(1):43–49. Exclusion: Not about accuracy and tool not standardized. [PubMed: 17220703]
149. Kelly PT. Breast cancer risk analysis: a genetic epidemiology service for families. J Genet Couns. 1992;1( 2):155–167. Exclusion: Not about accuracy and tool not standardized. [PubMed: 24242006]
150. Kelly PT. Breast cancer risk assessment and counseling: A clinician's guide. Breast J. 1997;3(6):311–31. Exclusion: Study type.
151. Kernohan G. A patient initiated computer program improved breast cancer screening practices in primary care. Evid Based Nurs. 1999;2(2):5. Exclusion: Study Type.
152. Kirk J, Brennan M, Houssami N. et al. An approach to the patient with a family history of breast cancer. Aust Fam Physician. 2006;35(12):43–47. Exclusion: Study type. [PubMed: 16489386]
153. Kokuer M, Naguib RN, Jancovic P. et al. Cancer risk analysis in families with hereditary nonpolyposis colorectal cancer. IEEE Transactions on Information Technology in Biomedicine. 2006;10(3):581–587. Exclusion: Narrative only. [PubMed: 16871728]
154. Kronborg O. Screening guidelines for colorectal cancer. Scand J Gastroenterol Suppl. 1992;27(192):123–129. Exclusion: Study type. [PubMed: 1439563]
155. Kuschel B, Hauenstein E, Kiechle M. et al. Hereditary breast and ovarian cancer - Current clinical guidelines in Germany. Breast Care. 2006;1(1):8–14. Exclusion: No data reported.
156. La Vecchia C, Parazzini F, Negri E. et al. Family history and risk of ovarian cancer. Int J Cancer. 1996;67(6):903–904. Exclusion: Only a mutation or prediction. [PubMed: 8824566]
157. Laghi L, Bianchi P, Roncalli M. et al. Re: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(18):1402–1403. Exclusion: Only a mutation or prediction. [PubMed: 15367575]
158. Leggatt V, Mackay J, Yates JR. Evaluation of questionnaire on cancer family history in identifying patients at increased genetic risk in general practice. BMJ. 1999;319(7212):757–758. Exclusion: Guideline or consensus statement. [PMC free article: PMC28230] [PubMed: 10488003]
159. Levin B, Barthel JS, Burt RW. et al. Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Cancer Netw. 2006;4(4):384–420. Exclusion: Study Type. [PubMed: 16569391]
160. Lipton LR, Johnson V, Cummings C. et al. Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic.[erratum appears in J Clin Oncol 2005 20;23(15):3652] Jpn J Clin Oncol. 2004;22(24):4934–4943. Exclusion: Not about accuracy and tool not standardized. [PubMed: 15611508]
161. Loader S, Shields C, Levenkron JC. et al. Patient vs. physician as the target of educational outreach about screening for an inherited susceptibility to colorectal cancer. Genet Test. 2002;6(4):281–290. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12537652]
162. Loukola A, de la Chapelle A, Aaltonen LA. Strategies for screening for hereditary non-polyposis colorectal cancer.[erratum appears in J Med Genet 2000;37(6):479–80] J Med Genet. 1999;36(11):819–822. Exclusion: Only a mutation or prediction. [PMC free article: PMC1734266] [PubMed: 10544224]
163. Lush DT. Screening programs in the population at large and in high-risk groups. Surg Oncol Clin N Am. 1996;5(3):545–552. Exclusion: Study type. [PubMed: 8829318]
164. Lynch HT, Fusaro RM, Lynch JF. Family history of cancer. Ann N Y Acad Sci. 1995;768:12–2. Exclusion: Study type. [PubMed: 8526341]
165. Mackay J, Schulz P, Rubinelli S. et al. Online Patient Education and Risk Assessment: project OPERA from Cancer backup. Putting inherited breast cancer risk information into context using argumentation theory. Patient Educ Couns. 2007;67(3 SPEC. ISS.):261–266. Exclusion: Does not apply to any of the research questions. [PubMed: 17590305]
166. Macrae F, Harris M. Re: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2005;97(12):936–937. Exclusion: No data reported. [PubMed: 15956656]
167. Mancuso C, Glendon G, Anson-Cartwright L. et al. Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire. Ann Epidemiol. 2004;14(1):36–43. Exclusion: Not about accuracy and tool not standardized. [PubMed: 14664778]
168. Mayer DK. Commentary on validation of a breast cancer risk assessment model in women with a positive family history. ONS Nursing Scan in Oncology 1994;3(5):. Exclusion: Narrative only.
169. Mayer DK. Commentary on validation of the Gail et al. model for predicting individual breast cancer risk. ONS Nursing Scan in Oncology. 1994;3(5):5–6. Exclusion: Narrative only.
170. McAllister M, O'Malley K, Hopwood P. et al. Management of women with a family history of breast cancer in the North West Region of England: training for implementing a vision of the future. J Med Genet. 2002;39(7):531–535. Exclusion: Narrative only. [PMC free article: PMC1735171] [PubMed: 12114490]
171. McCance KL, Jorde LB. Evaluating the genetic risk of breast cancer. Nurse Pract 1998;23(8):14-,16,19–20 passim. Exclusion: Study type. [PubMed: 9718599]
172. McCann S, MacAuley D. Management of familial breast and ovarian cancer cases. Br J Gen Pract. 2002;52(474):5. Exclusion: No data reported. [PMC free article: PMC1314205] [PubMed: 11791820]
173. McConnell JC. Colonoscopy in patients with a primary family history of colon cancer. Dis Colon Rectum. 1990;33(3):25. Exclusion: No data reported. [PubMed: 2311473]
174. McGuigan KA, Ganz PA, Breant C. Agreement between breast cancer risk estimation methods. J Natl Cancer Inst. 1996;88(18):1315–1317. Exclusion: Guideline or consensus statement. [PubMed: 8797772]
175. McTiernan A, Kuniyuki A, Yasui Y. et al. Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(4):333–338. Exclusion: Only a mutation or prediction. [PubMed: 11319173]
176. Miller BE. Breast cancer risk assessment in patients seen in a gynecologic oncology clinic. Internatl J Gynecol Cancer. 2002;12(4):389–393. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12144688]
177. Morantz C. ACS Guidelines for Early Detection of Cancer. Am Fam Physician. 2004;69(8):201. Exclusion: Study Type. [PubMed: 15117023]
178. Moslehi R, Solehdin F, Malik I. et al. Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome. Am J Med Genet. 1998;78(4):386–387. Exclusion: Not about accuracy and tool not standardized. [PubMed: 9714446]
179. Mouchawar J, Klein CE, Mullineaux L. Colorado family physicians' knowledge of hereditary breast cancer and related practice. J Cancer Educ. 2001;16(1):33–37. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11270897]
180. Murff HJ, Byrne D, Haas JS. et al. Race and family history assessment for breast cancer. J Gen Intern Med. 2005;20:75–8. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC1490028] [PubMed: 15693932]
181. Murff HJ, Byrne D, Syngal S. Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med. 2004;27(3):239–245. Exclusion: Not about accuracy and tool not standardized. [PubMed: 15450637]
182. Nanda R, Schumm LP, Cummings S. et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005;294(15):1925–1933. Exclusion: Only a mutation or prediction. [PubMed: 16234499]
183. Narod SA, Dupont A, Cusan L. et al. The impact of family history on early detection of prostate cancer. Nat Med. 1995;1(2):99–101. Exclusion: Only a mutation or prediction. [PubMed: 7585019]
184. Narod SA, Ginsburg O, Jothy S. Family history and colorectal cancer. N Engl J Med. 1995;332(23):1578–1579. Exclusion: Not about accuracy and tool not standardized. [PubMed: 7739715]
185. Narod S, Lynch H, Conway T. et al. Increasing incidence of breast cancer in family with BRCA1 mutation. Lancet. 1993;341(8852):1101–1102. Exclusion: Study Type. [PubMed: 8097005]
186. Nersesyan AK. Re: Rajeswari,N., Ahuja,Y.R., Malani,U., Chandrashekar,S., Balakrishna,N., Rao,K.V. and Khar,A. (2000) Risk assessment in the first degree female relatives of breast cancer patients using the alkaline Comet assay. Carcinogenesis 2000;21:557–561. [Letter to the Editor]. Carcinogenesis 2001;22(4):67. Exclusion: Study Type. [PubMed: 10753185]
187. Newton P, Hannay DR, Laver R. The presentation and management of female breast symptoms in general practice in Sheffield. Fam Pract. 1999;16(4):360–365. Exclusion: No cancer of interest. [PubMed: 10493705]
188. Nippert I, Schlegelberger B, Consortium H. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Munster. Community Genet. 2003;6(4):249–258. Exclusion: Not about accuracy and tool not standardized. [PubMed: 15331871]
189. O'Riordan MM. Identifying patients at low risk of bowel cancer: personal or familial risk factors need to be mentioned. BMJ. 2003;327(7419):871–872. Exclusion: No data reported. [PMC free article: PMC214108] [PubMed: 14551120]
190. Ormond KE, Bellcross C, Weissman S. Genetic risk assessment and BRCA mutation testing. Ann Intern Med 304;144(4):303–304. Exclusion: Narrative only. [PubMed: 16490919]
191. Palomaki GE, McClain MR, Steinort K. et al. Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women. Genet Med. 2006;8(3):161–168. Exclusion: Guideline or consensus statement. [PubMed: 16540750]
192. Paltiel O, Friedlander Y, Deutsch L. et al. The interval between cancer diagnosis among mothers and offspring in a population-based cohort. Fam Cancer. 2007;6(1):121–129. Exclusion: Not about accuracy and tool not standardized. [PubMed: 17216543]
193. Parazzini F, La Vecchia C, Chatenoud L. et al. Re: Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst. 1996;88(14):1003–1004. Exclusion: Not about accuracy and tool not standardized. [PubMed: 8667420]
194. Park JG, Vasen HF, Park YJ. et al. Suspected HNPCC and Amsterdam criteria II: evaluation of mutation detection rate, an international collaborative study. Int J Colorectal Dis. 2002;17(2):109–114. Exclusion: Only a mutation or prediction. [PubMed: 12014418]
195. Pasini B, Casalis Cavalchini GC, Genovese T. et al. Evaluating breast cancer risk: available models to assess individual breast cancer risk and probability to be a BRCA mutation carrier. J Exp Clin Cancer Res. 2002;21(3 Suppl):23–29. Exclusion: Study type. [PubMed: 12585650]
196. Pelucchi C, Negri E, Tavani A. et al. Attributable risk for familial breast cancer. Int J Cancer. 2002;102(5):548–549. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12432562]
197. Pharoah PDP, Mackay J. Absolute risk of breast cancer in women at increased risk: A more useful clinical measure than relative risk? Breast Cancer Res Treat. 1998;7(5):255–259. Exclusion: Study Type.
198. Pharoah PDP, Stratton JF, Mackay J. Screening for breast and ovarian cancer: The relevance of family history. Br Med Bull. 1998;54(4):823–838. Exclusion: Narrative only. [PubMed: 10367417]
199. Pichert G, Bolliger B, Buser K. et al. Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol. 2003;14(1):9–19. Exclusion: Study type. [PubMed: 12488287]
200. Pinsky PF, Kramer BS, Reding D. et al. Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2003;157(9):792–799. Exclusion: Presents only aggregate data. [PubMed: 12727673]
201. Rajkumar GN, Small DR, Conn IG. Computerised triage in a prostate assessment clinic. Prostate Cancer Prostatic Dis. 2004;7(2):118–121. Exclusion: Not about accuracy and tool not standardized. [PubMed: 15175663]
202. Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med. 2003;5( 5):353–363. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC2692576] [PubMed: 14501830]
203. Ramsey SD, Burke W, Pinsky L. et al. Family history assessment to detect increased risk for colorectal cancer: conceptual considerations and a preliminary economic analysis. Cancer Epidemiol Biomarkers Prev. 2005;14(11 Pt 1):2494–2500. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC2692569] [PubMed: 16284369]
204. Rauscher GH, Sandler DP. Validating cancer histories in deceased relatives. Am J Epidemiol. 2005;16( 2):262–265. Exclusion: No cancer of interest. [PubMed: 15703544]
205. Rhodes DJ. Concise review for clinicians. Identifying and counseling women at increased risk for breast cancer. Mayo Clin Proc. 2002;77(4):355–361. Exclusion: Study type. [PubMed: 11936931]
206. Richards Martin PM, Hallowell Nina, Green Josephine M. et al. Counseling families with hereditary breast and ovarian cancer: A psychosocial perspective. J Genet Couns. 1995;4(3):219–233. Exclusion: No data reported. [PubMed: 24234371]
207. Ripley M, Sullivan D, Evans J. The role of patient users in cancer genetics services in primary care. Fam Cancer. 2007;6(2):241–248. Exclusion: Not about accuracy and tool not standardized. [PubMed: 17520354]
208. Rodriguez-Bigas MA, Vasen HF, O'Malley L. et al. Health, life, and disability insurance and hereditary nonpolyposis colorectal cancer. Am J Hum Genet. 1998;62(3):736–737. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC1376947] [PubMed: 9497250]
209. Rodriguez-Bigas MA. Genetic testing is important in families with a history suggestive of hereditary non-polyposis colorectal cancer even if the Amsterdam criteria are not fulfilled. Br J Surg. 1997;84(7):1027–1028. Exclusion: No data reported. [PubMed: 9240161]
210. Rodriguez-Moranta F, Castells A, Andreu M. et al. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol. 2006;101(5):1104–1111. Exclusion: Guideline or consensus statement. [PubMed: 16696788]
211. Roemeling S, Roobol MJ, de Vries SH. et al. Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol. 2006;175(4):1332–1336. Exclusion: Does not apply to any of the research questions. [PubMed: 16515992]
212. Rose PW, Murphy M, Munafo M. et al. Improving the ascertainment of families at high risk of colorectal cancer: a prospective GP register study. Br J Gen Pract. 2004;54(501):267–271. Exclusion: Guideline or consensus statement. [PMC free article: PMC1314851] [PubMed: 15113493]
213. Rose PW, Suchard MA. Screening people with a family history of cancer. Taking a family history in primary care is important. BMJ. 1997;315(7118):130. Exclusion: No data reported. [PMC free article: PMC2127817] [PubMed: 9390066]
214. Rose PW, Watson E, Yudkin P. et al. Referral of patients with a family history of breast/ovarian cancer—GPs' knowledge and expectations. Fam Pract. 2001;18(5):487–490. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11604368]
215. Rothenberger DA, Dalberg DL, Leininger A. Minnesota Colorectal Cancer Initiative: successful development and implementation of a community-based colorectal cancer registry. Dis Colon Rectum. 2004;47(10):1571–1577. Exclusion: Not about accuracy and tool not standardized. [PubMed: 15540283]
216. Ruo L, Cellini C, La Calle JPJ. et al. Limitations of family cancer history assessment at initial surgical consultation. Dis Colon Rectum. 2001;44(1):98–103. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11805570]
217. Sadler GR, Wasserman L, Fullerton JT. et al. Supporting patients through genetic screening for cancer risk. Medsurg Nurs. 2004;13(4):233–246. Exclusion: No data reported. [PubMed: 15384477]
218. Saraiya M, Coughlin SS, Burke W. et al. The role of family history in personal prevention practices among US women physicians. Community Genet. 2001;4(2):102–108. Exclusion: Not about accuracy and tool not standardized.
219. Satheshkumar T, Saklani AP, Nagbhushan JS. et al. Documenting family history in colorectal cancer patients - A retrospective audit. International Journal of Surgery. 2004;2( 1):22–23. Exclusion: Not about accuracy and tool not standardized.
220. Sauven P. Association of Breast Surgery Family History Guidelines Panel. Guidelines for the management of women at increased familial risk of breast cancer. Eur J Cancer. 2004;40(5):653–665. Exclusion: Study Type. [PubMed: 15010065]
221. Schaid DJ. Re: probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89(21):1632–1634. Exclusion: No data reported. [PubMed: 9362169]
222. Scheuner MT, Wang SJ, Raffel LJ. et al. Family history: A comprehensive genetic risk assessment method for the chronic conditions of adulthood. Am J Med Genet. 1997;71(3):315–324. Exclusion: Guideline or consensus statement. [PubMed: 9268102]
223. Schroy PC, Barrison AF, Ling BS. et al. Family history and colorectal cancer screening: A survey of physician knowledge and practice patterns. Am J Gastroenterol. 2002;97(4):1031–1036. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12008667]
224. Schwartz MD, Tercyak KP, Peshkin BN. et al. Can a computer-based system be used to educate women on genetic testing for breast cancer susceptibility? Nat Clin Pract Oncol. 2005;2(1):24–25. Exclusion: Not about accuracy and tool not standardized. [PubMed: 16264852]
225. Scott RG, Edwards JT, Mendelson RM. et al. Detecting people at higher risk for colorectal neoplasia in a community-based screening program. Med J Aust. 2003;179(6):32. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12964919]
226. Selby JV. Family history and colorectal cancer. N Engl J Med. 1995;332(23):1578–1579. Exclusion: Only a mutation or prediction. [PubMed: 7739716]
227. Selvachandran SN, Hodder RJ, Ballal MS. et al. Prediction of colorectal cancer by a patient consultation questionnaire and scoring system: a prospective study. Lancet. 2002;360(9329):278–283. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12147370]
228. Shanley S, Myhill K, Doherty R. et al. Delivery of cancer genetics services: The Royal Marsden telephone clinic model. Fam Cancer. 2007;6(2):213–219. Exclusion: Does not apply to any of the research questions. [PubMed: 17508269]
229. Sifri RD, Wender R, Paynter N. Cancer risk assessment from family history: gaps in primary care practice. J Fam Pract. 2002;51(10):85. Exclusion: Presents only aggregate data. [PubMed: 12836643]
230. Simon MS, Korczak JF, Yee CL. et al. Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women's Contraceptive and Reproductive Experiences Study. Jpn J Clin Oncol. 2006;24(16):2498–2504. Exclusion: Only a mutation or prediction. [PubMed: 16735703]
231. Sladden MJ, Ward JE. Australian general practitioners' views and use of colorectal cancer screening tests. Med J Aust. 1999;170(3):110–113. Exclusion: Not about accuracy and tool not standardized. [PubMed: 10065121]
232. Snyder LA, Soballe DB, Lahl LL. et al. Development of the breast cancer education and risk assessment program. Oncol Nurs Forum. Online. 2003;30(5):803–808. Exclusion: Guideline or consensus statement. [PubMed: 12949593]
233. Spigelman AD. Current surgical practice in screening for colorectal cancer based on family history criteria. Br J Surg. 1999;86(3):42. Exclusion: No data reported. [PubMed: 10201793]
234. Standard Task Force, American Society, Collaborative Group. Practice parameters for the identification and testing of patients at risk for dominantly inherited colorectal cancer. Dis Colon Rectum. 2001;44(10):140–1. Exclusion: Study Type. [PubMed: 11598465]
235. Stirling D, Porteous ME, Evans DG. et al. Familial ovarian cancer screening. Am J Clin Oncol. 2006;24(6):e1. Exclusion: Study Type. [PubMed: 16484689]
236. Stormorken AT, Muller W, Lemkemeyer B. et al. Prediction of the outcome of genetic testing in HNPCC kindreds using the revised Amsterdam criteria and immunohistochemistry. Fam Cancer. 2001;1(34):169–173. Exclusion: Guideline or consensus statement. [PubMed: 14574174]
237. Summerton N, Garrood PVA. The family history in family practice: A questionnaire study. Fam Pract. 1997;14(4):285–288. Exclusion: Not about accuracy and tool not standardized. [PubMed: 9283847]
238. Sutherland HJ, Lacroix J, Knight J. et al. The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in Ontario. J Clin Epidemiol. 2001;54(1):93–98. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11165472]
239. Suzuki T, Matsuo K, Wakai K. et al. Effect of familial history and smoking on common cancer risks in Japan. Cancer. 2007;109(10):2116–2123. Exclusion: Does not apply to any of the research questions. [PubMed: 17410537]
240. Syngal S, Fox EA, Eng C. et al. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet. 2000;37(9):641–645. Exclusion: Guideline or consensus statement. [PMC free article: PMC1734690] [PubMed: 10978352]
241. Terhaar sive, Droste JS, Heine GDN. et al. On attitudes about colorectal cancer screening among gastrointestinal specialists and general practitioners in the Netherlands. World J Gastroenterol. 2006;12(32):5201–5204. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC4088020] [PubMed: 16937533]
242. Tinley ST, Lynch HT. Integration of family history and medical management of patients with hereditary cancers. Cancer. 1999;86(11 Suppl):2525–2532. Exclusion: Narrative only. [PubMed: 10630178]
243. Tozer D, Lugton C. Cancer genetics in rural primary care: A pilot nurse-led service using a new mobile IT system. Fam Cancer. 2007;6(2):221–229. Exclusion: Does not apply to any of the research questions. [PubMed: 17520350]
244. Trafalis DTP, Athanassiou A. A guideline for the management of women at substantially increased risk of breast cancer development. Journal of B.U.On. 2005;10(4):443–458. Exclusion: Narrative only. [PubMed: 17357201]
245. Tudiver F, Guibert R, Haggerty J. et al. What influences family physicians' cancer screening decisions when practice guidelines are unclear or conflicting? J Fam Pract. 2002;51(9):76. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12366894]
246. Tyagi A, Morris J. Using decision analytic methods to assess the utility of family history tools. Am J Prev Med. 2003;24(2):199–207. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12568827]
247. Umar A, Boland CR, Terdiman JP. et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–268. Exclusion: Study Type. [PMC free article: PMC2933058] [PubMed: 14970275]
248. Unic I, Stalmeier PFM, Peer PGM. et al. A review on family history of breast cancer: Screening and counseling proposals for women with familial (non-hereditary) breast cancer. Patient Educ Couns. 1997;32(12):117–12. Exclusion: Study Type. [PubMed: 9355579]
249. Vahteristo P, Eerola H, Tamminen A. et al. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer. 2001;84(5):704–708. Exclusion: Guideline or consensus statement. [PMC free article: PMC2363799] [PubMed: 11237395]
250. van Asperen CJ, Jonker MA, Jacobi CE. et al. Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev. 2004;13(1):87–93. Exclusion: Guideline or consensus statement. [PubMed: 14744738]
251. van Asperen CJ, Tollenaar RA, Krol-Warmerdam EM. et al. Possible consequences of applying guidelines to healthy women with a family history of breast cancer. Eur J Hum Genet. 2003;11(8):633–636. Exclusion: Not about accuracy and tool not standardized. [PubMed: 12891386]
252. Vance GH. Testing for BRCA1 in hereditary breast cancer. JAMA. 1995;273(11):845–846. Exclusion: No data reported. [PubMed: 7869550]
253. Vasen HF, Watson P, Mecklin JP. et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453–1456. Exclusion: Only a mutation or prediction. [PubMed: 10348829]
254. Verkooijen HM, Fioretta G, Chappuis PO. et al. Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results. Ann Oncol. 2004;15(2):350–353. Exclusion: Not about accuracy and tool not standardized. [PubMed: 14760133]
255. Vijay V, Saunders C. Re: A strong family history of breast cancer [3] Breast Cancer Res Treat. 2000;9(5):295–296. Exclusion: No data reported.
256. Vogel VG. Assessing risk of breast cancer: Tools for evaluating a patient's 5- year and lifetime probabilities. Postgrad Med. 1999;105(6):49–58. Exclusion: Study type.
257. Vogel VG. Screening behaviors among relatives of breast cancer patients. Am J Public Health. 1992;82(10):142. Exclusion: Study Type. [PMC free article: PMC1695855] [PubMed: 1415873]
258. Wagner A, Tops C, Wijnen JT. et al. Genetic testing in hereditary non-polyposis colorectal cancer families with a MSH2, MLH1, or MSH6 mutation. J Med Genet. 2002;39(11):833–837. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC1735004] [PubMed: 12414824]
259. Wallace E, Hinds A, Campbell H. et al. A cross-sectional survey to estimate the prevalence of family history of colorectal, breast and ovarian cancer in a Scottish general practice population. Br J Cancer. 2004;91(8):1575–1579. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC2409922] [PubMed: 15381929]
260. Walter FM, Kinmonth AL, Hyland F. et al. Experiences and expectations of the new genetics in relation to familial risk of breast cancer: a comparison of the views of GPs and practice nurses. Fam Pract. 2001;18(5):491–494. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11604369]
261. Warner E, Heisey RE, Goel V. et al. Hereditary breast cancer. Risk assessment of patients with a family history of breast cancer. Can Fam Physician. 1999;45:104–112. Exclusion: Study Type. [PMC free article: PMC2328077] [PubMed: 10889863]
262. Washburn NJ, Sommer VK, Spencer SE. et al. Outpatient genetic risk assessment in women with breast cancer: one center's experience. Clin J Oncol Nurs. 2005;9(1):49–53. Exclusion: Study Type. [PubMed: 15751498]
263. Welkenhuysen M, Evers-Kiebooms G. The reactions of general practitioners, nurses and midwives in Flanders concerning breast cancer risks in a high-risk situation. Community Genet. 2003;6(4):206–213. Exclusion: Not about accuracy and tool not standardized. [PubMed: 15331866]
264. Wilcox-Hannold PM. Breast cancer and gene testing: risk, rationale, and responsibilities of primary care providers. Lippincott's Primary Care Practice. 1998;2(3):271–283. Exclusion: Study type. [PubMed: 9644442]
265. Wilkins-Haug L, Erickson K, Hill L. et al. Obstetrician-gynecologists' opinions and attitudes on the role of genetics in women's health. Journal of Womens Health & Gender-Based Medicine. 2000;9( 8):873–879. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11074953]
266. Wilkins-Haug Louise, Erickson Kristine, Hill Lauren. et al. Obstetrician-gynecologists' opinions and attitudes on the role of genetics in women's health. J Womens Health Gend Based Med. 2000;9(8):873–879. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11074953]
267. Williams GL, Gray J, Beynon J. Cancer genetics clinics and the surgeon: a valuable role for family history screening. Ann R Coll Surg Engl. 2007;89(2):127–129. Exclusion: Not about accuracy and tool not standardized. [PMC free article: PMC1964557] [PubMed: 17346404]
268. Wilson BJ, Torrance N, Mollison J et al. Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions. Health Technology Assessment (Winchester, England). 2005;9(3. Exclusion: Does not apply to any of the research questions. [PubMed: 15694064]
269. Winawer SJ, Fletcher RH, Miller L. et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology. 1997;112(2):594–64. Exclusion: Study Type. [PubMed: 9024315]
270. Winawer SJ, St John DJ, Bond JH. et al. Prevention of colorectal cancer: guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer. Bull World Health Organ. 1995;73(1):7–10. Exclusion: Only a mutation or prediction. [PMC free article: PMC2486580] [PubMed: 7704928]
271. Winawer S, Fletcher R, Rex D. et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124( 2):544–560. Exclusion: Study Type. [PubMed: 12557158]
272. Wolpert CM, Speer MC. Harnessing the power of the pedigree. J Midwifery Womens Health. 2005;50(3):189–196. Exclusion: Study type. [PubMed: 15894996]
273. Yasui Y, Newcomb PA, Trentham-Dietz A. et al. Familial relative risk estimates for use in epidemiologic analyses. Am J Epidemiol. 2006;164(7):697–705. Exclusion: Only a mutation or prediction. [PubMed: 16923773]
274. Yusoff IF, Hoffman NE, Ee HC. Colonoscopic surveillance for family history of colorectal cancer: are NHMRC guidelines being followed? Med J Aust. 2002;176(4):151–154. Exclusion: Not about accuracy and tool not standardized. [PubMed: 11913913]
275. Zarchy TM, Ershoff D. Risk of colorectal cancer in families of patients with adenomatous polyps. N Engl J Med. 1996;334(20):1339–1340. Exclusion: No data reported. [PubMed: 8609964]